PMID- 25328348
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20141020
LR  - 20211021
IS  - 1002-0829 (Print)
IS  - 1002-0829 (Linking)
VI  - 24
IP  - 5
DP  - 2012 Oct
TI  - Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenia: A 
      systematic review.
PG  - 250-61
LID - 10.3969/j.issn.1002-0829.2012.05.002 [doi]
AB  - BACKGROUND: There is increasing interest in the role of brain-derived 
      neurotrophic factor (BDNF) in the onset and course of schizophrenia, but there 
      are conflicting reports about serum levels of BDNF in patients with 
      schizophrenia. AIM: Conduct a meta-analysis combining studies from China and 
      other countries that have evaluated the relationship of serum BDNF levels to 
      schizophrenia. METHOD: We used Cochrane methodology and RevMan 5.1 software to 
      identify and pool the results of studies. Electronic searches of western and 
      Chinese registries and follow-up assessment of references located 268 potential 
      articles. Twenty-five articles (20 in English and 5 in Chinese) published before 
      December 2011 that used case-control methods, included patients with 
      schizophrenia who had no concurrent disorders, and used ELISA technology to 
      assess serum BDNF were included in the analysis. The main outcome was the pooled 
      standardized mean difference (SMD) between cases and controls. The quality of the 
      studies was independently assessed by two raters using the GRADE system. The 
      heterogeneity, sensitivity and potential publication bias of the studies was 
      evaluated using RevMan. RESULTS: The pooled sample included 1663 patients with 
      schizophrenia and 1355 controls. Fifteen of the included studies were rated as 
      'poor quality' and 10 were rated as 'very poor quality'. The results of the 
      studies were quite heterogenous (I(2)=95%) but subgroup analyses found that the 
      heterogeneity was not related to country of origin, sample size, age, gender, 
      prior use of antipsychotic medication, or study quality. The pooled SMD (computed 
      using a random-effect model because of study heterogeneity) was -0.74 (95% CI, 
      -0.99 approximately -0.50; Z=5.99, p<0.001). Sensitivity analysis found that the result was 
      stable and there was no evidence of publication bias. CONCLUSION: Despite the 
      robust statistical findings of lower serum BDNF in patients with schizophrenia 
      than in controls, given the low quality of the available studies and the 
      substantial heterogeneity between studies, the evidence of lower serum BDNF in 
      patients with schizophrenia must be considered 'weak'. The potential use of serum 
      BDNF as a biomarker for schizophrenia must wait until higher-quality prospective 
      studies that follow patients over time and that use uniform selection and 
      monitoring procedures confirm these preliminary results.
FAU - Cui, Huiru
AU  - Cui H
AD  - Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, 
      Shanghai, China.
FAU - Jin, Yi
AU  - Jin Y
AD  - Institute of Psychology, Chinese Academy of Sciences, Beijing, China.
FAU - Wang, Jijun
AU  - Wang J
AD  - Center for Cognition and Brain Disorders, Hangzhou Normal University, Hangzhou, 
      Zhejiang Province, China.
FAU - Weng, Xuchu
AU  - Weng X
AD  - Institute of Psychology, Chinese Academy of Sciences, Beijing, China ; Center for 
      Cognition and Brain Disorders, Hangzhou Normal University, Hangzhou, Zhejiang 
      Province, China.
FAU - Li, Chunbo
AU  - Li C
AD  - Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, 
      Shanghai, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Shanghai Arch Psychiatry
JT  - Shanghai archives of psychiatry
JID - 9891453
PMC - PMC4198873
COIS- Conflict of interest: The authors report no conflict of interest related to this 
      manuscript
EDAT- 2012/10/01 00:00
MHDA- 2012/10/01 00:01
PMCR- 2012/10/01
CRDT- 2014/10/21 06:00
PHST- 2012/03/22 00:00 [received]
PHST- 2012/08/22 00:00 [accepted]
PHST- 2014/10/21 06:00 [entrez]
PHST- 2012/10/01 00:00 [pubmed]
PHST- 2012/10/01 00:01 [medline]
PHST- 2012/10/01 00:00 [pmc-release]
AID - sap-24-05-250 [pii]
AID - 10.3969/j.issn.1002-0829.2012.05.002 [doi]
PST - ppublish
SO  - Shanghai Arch Psychiatry. 2012 Oct;24(5):250-61. doi: 
      10.3969/j.issn.1002-0829.2012.05.002.